Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Director departure
Appointed director
|
|
Skye Bioscience, Inc. (NMUS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/03/2023 |
PRE 14C
| Form PRE 14C - Other preliminary information statements: |
| 08/22/2023 |
4
| Schwab Andrew J. (10% Owner) has filed a Form 4 on Skye Bioscience, Inc.|
Txns:
| Granted 267,602,039 shares
@ $0
Granted 10,558,878 shares
@ $0
Granted 684,361,447 shares
@ $0.0103, valued at
$7M
Granted 161,944,872 shares
@ $0.0103, valued at
$1.7M
Granted 6,389,921 shares
@ $0.0103, valued at
$65.8k
Granted 426,348,120 warrants
@ $0.0206, valued at
$8.8M
|
|
| 08/22/2023 |
3
| Schwab Andrew J. (10% Owner) has filed a Form 3 on Skye Bioscience, Inc. |
| 08/22/2023 |
3
| Grayson Paul A. (Director) has filed a Form 3 on Skye Bioscience, Inc. |
| 08/21/2023 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...|
Docs:
|
"2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION",
"COMMON STOCK PURCHASE WARRANT SKYE BIOSCIENCE, INC.",
"SECURED CONVERTIBLE PROMISSORY NOTE",
"COMMON STOCK PURCHASE WARRANT SKYE BIOSCIENCE, INC.",
"SECURITIES PURCHASE AGREEMENT",
"REGISTRATION RIGHTS AGREEMENT",
"SKYE BIOSCIENCE, INC. SECURED NOTE AND WARRANT PURCHASE AGREEMENT",
"INDEMNIFICATION AGREEMENT",
"Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody" |
|
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/27/2023 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/17/2023 |
4
| Emerald Health Sciences Inc. (10% Owner) has filed a Form 4 on Skye Bioscience, Inc.|
Txns:
| Granted 16,641,486 shares
@ $0.017, valued at
$282.9k
Granted 41,379,164 shares
@ $0.0386, valued at
$1.6M
Acquired 9,141,486 warrants
@ $0.151, valued at
$1.4M
Disposed/sold 9,141,486 warrants
@ $0.017, valued at
$155.4k
Bought 2,500,000 options to buy
@ $0.0386, valued at
$96.5k
Disposed/sold 2,500,000 options to buy
@ $0.0386, valued at
$96.5k
|
|
| 02/23/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Secu... |
| 01/09/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 01/09/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/09/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/09/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/06/2023 |
4
| TYLE PRAVEEN (Director) has filed a Form 4 on Skye Bioscience, Inc.|
Txns:
| Granted 250,000 options to buy
@ $0.017, valued at
$4.3k
|
|
| 01/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 12/16/2022 |
8-K
| Quarterly results |
| 11/23/2022 |
8-K
| Quarterly results |
| 11/15/2022 |
3/A
| Form 3/A - Initial statement of beneficial ownership of securities: [Amend] |
| 11/15/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/15/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/15/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/03/2022 |
8-K
| Quarterly results |
| 09/01/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/31/2022 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/12/2022 |
PREM14A
| Form PREM14A - Preliminary proxy statements relating to merger or acquisition: |
| 07/20/2022 |
8-K
| Quarterly results |
| 06/17/2022 |
8-K
| Quarterly results |
| 05/23/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 05/06/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
|
|
|